Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEMAGEN DIAGNOSTICS (HMGN) -- Ignore unavailable to you. Want to Upgrade?

To: chalu2 who wrote (26)	12/24/1998 9:09:00 AM
From: Walter Morton	Respond to of 98

That's right, but they have over $5 million in cash, another $3 million in cash coming from the $25 million IMNX out of court settlement, and a $33 million agreement with the largest vaccine company in the world. CIST is a start-up company that is concentating on research in the same industry and has enough cash to buy HMGN. So, don't turn your nose up to the $.23 per share price. The only reason CIST is $.23 is because of the number of shares outstanding (of which they have started to reduce). Here is a little background: cistronbio.com (there are several press releases on one page) cistronbio.com HMGN has virtually no cash, but a very good product offering and better marketing skills. Further HMGN seems to be one of the few small companies in this field that has managed to make profits. Either way, HMGN is understated and will be bought buy somebody soon.